The overall goal of this project is to develop dynamic MRI methods, using macromolecular contrast media (MMCM) enhancement, for monitoring the response of tumors to inhibitors of angiogenesis. Our previous studies have shown that MMCM can be used with MRI to estimate fractional blood volume (fBV), as a measure of vascularity, and the endothelial transfer coefficient (KPS), as a measure of tumor vascular leakiness. The overall hypothesis is that inhibitors of angiogenesis alter the structure and function of tumor blood vessels, including their leakiness to macromolecular solutes, in ways that can be detected and quantified by dynamic MRI. The approach takes advantage of the well-documented macromolecular leakiness of tumor blood vessels. Planned studies will determine if the MR/measurements can serve as biomarkers of tumor angiogenesis and, when used early in the course of treatment, can predict the long-term response to antiangiogenic therapy. Our planned studies will determine the utility of the MRI methods in assessing angiogenesis inhibitors that act through vascular endothelial growth factor (VEGF) and other elements implicated in angiogenesis. They will also elucidate the effect of antiangiogenic drugs on the delivery of cytotoxic agents to tumor cells. Complementary fluorescence, confocal, and electron microscopic studies, with a focus on changes induced in endothelial cells, pericytes, and basement membranes of tumor vessels by angiogenesis inhibitors, will give insight into cellular changes underlying vascular functions assessed by the MRI methods. The MRI methods should facilitate the screening of angiogenesis inhibitors in preclinical models, should strengthen the design of clinical trials of antiangiogenic drugs - including trials using combinations of angiogenesis inhibitors and cytotoxic drugs, and ultimately should improve assessment of clinical responses to antiangiogenic therapies in cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA082923-05
Application #
6820187
Study Section
Diagnostic Imaging Study Section (DMG)
Program Officer
Menkens, Anne E
Project Start
1999-09-01
Project End
2009-06-30
Budget Start
2004-08-13
Budget End
2005-07-31
Support Year
5
Fiscal Year
2004
Total Cost
$433,266
Indirect Cost
Name
University of California San Francisco
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sennino, Barbara; Ishiguro-Oonuma, Toshina; Schriver, Brian J et al. (2013) Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 73:3692-703
Cyran, Clemens C; Fu, Yanjun; Rogut, Victor et al. (2013) Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model. Acad Radiol 20:1256-63
Baluk, Peter; Hogmalm, Anna; Bry, Maija et al. (2013) Transgenic overexpression of interleukin-1? induces persistent lymphangiogenesis but not angiogenesis in mouse airways. Am J Pathol 182:1434-47
Cyran, Clemens C; Sennino, Barbara; Fu, Yanjun et al. (2012) Permeability to macromolecular contrast media quantified by dynamic MRI correlates with tumor tissue assays of vascular endothelial growth factor (VEGF). Eur J Radiol 81:891-6
Banfi, Andrea; von Degenfeld, Georges; Gianni-Barrera, Roberto et al. (2012) Therapeutic angiogenesis due to balanced single-vector delivery of VEGF and PDGF-BB. FASEB J 26:2486-97
Sennino, Barbara; Ishiguro-Oonuma, Toshina; Wei, Ying et al. (2012) Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2:270-87
Witte, Marlys H; Dellinger, Michael T; McDonald, Donald M et al. (2011) Lymphangiogenesis and hemangiogenesis: potential targets for therapy. J Surg Oncol 103:489-500
You, Weon-Kyoo; Sennino, Barbara; Williamson, Casey W et al. (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 71:4758-68
Falcon, Beverly L; Pietras, Kristian; Chou, Jeyling et al. (2011) Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B. Am J Pathol 178:2920-30
Falcon, Beverly L; Barr, Sharon; Gokhale, Prafulla C et al. (2011) Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 71:1573-83

Showing the most recent 10 out of 66 publications